Future Perspectives: Can Innovative Topical Therapies Like Ruxolitinib Reduce Systemic Treatment Dependency in Pediatric AD?

James Song, MD, FAAD, discusses how emerging topical JAK inhibitors like ruxolitinib cream may reduce the necessity for systemic therapies in select pediatric atopic dermatitis patients by effectively controlling moderate disease and potentially serving as long-term maintenance therapy with a favorable safety profile.